Skip to content

Synergus RWE is now part of athagoras Medtech. For current services and contact, visit medtech.athagoras.com

Go to athagoras Medtech
Archived article. This article was published by Synergus RWE on 08 Dec 2022 and is kept for reference. For current insights visit athagoras Medtech.

← Knowledge base

France launches fast-track process for reimbursement of digital solutions

France has a long history of testing different programs to include digital health in the healthcare.

Inspired by the German DiGA solution, they are in the process to introduce a pathway for conditional reimbursement (PECA) while the missing evidence is generated. The plan is that this will be available in2023.

The scope of this is either:

  • Remote monitoring solutions where there is no existing ‘generic line’ for the specific indication.
  • Any solution involving the patient that can show a therapeutic benefit (DTx)

The criteria to be eligible for this pathway is:

  • Potential of a meaningful clinical benefit.
  • Ability to develop to close the evidence gap during the period of conditional reimbursement.

The reimbursement will cover a 12-months period and is conditioned by a sustainable reimbursement dossier submission within 6 months of the start of the PECA for digital therapeutic devices (DTx) and within 9 months for remote monitoring solutions.

Want to understand more:

Related articles